Welcome to our dedicated page for Bio Green Med Solution SEC filings (Ticker: BGMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Bio Green Med Solution, Inc. (BGMS) brings together the company’s official reports to the U.S. Securities and Exchange Commission, including Form 8-K current reports and other key documents. These filings describe how the company has transitioned from its former identity as Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, to a diversified business focused primarily on fire safety protection and distribution activities anchored by its acquisition of FITTERS Sdn. Bhd. in Malaysia.
Through its 8-K filings, Bio Green Med Solution, Inc. discloses material events such as the completion of the FITTERS Sdn. Bhd. share exchange transaction, the Asset Purchase Agreement with Tethra Biosciences Inc. for the sale of patent rights related to plogosertib, and the liquidation of its UK subsidiary, Cyclacel Limited. These documents also cover capital markets actions, including a one-for-fifteen reverse stock split of its common stock, Warrant Exchange Agreements that exchanged existing warrants for new common shares, and a Nasdaq notice regarding the minimum Market Value of Publicly Held Shares requirement for its 6% Convertible Exchangeable Preferred Stock (BGMSP).
Filings further address governance and compensation matters, such as the resignation and appointment of independent directors, committee assignments for the Audit, Compensation and Organization, and Nominating and Governance Committees, and confirmation of director independence and financial literacy under SEC and Nasdaq standards. Dividend declarations on the company’s 6% Convertible Exchangeable Preferred Stock are also documented in Form 8-K reports.
On this page, users can access Bio Green Med Solution, Inc.’s SEC filings as they are made available from EDGAR and review AI-generated summaries that explain the main points of lengthy documents, including 10-K annual reports, 10-Q quarterly reports, and Form 4 insider transaction reports where applicable. These tools help readers quickly understand complex regulatory disclosures, track changes in the company’s business focus, and follow developments affecting its common and preferred equity securities.
Report overview: This Schedule 13G/A states that Kua Khai Loon beneficially owns 805,695 shares of Bio Green Med Solution, Inc. common stock, representing 16.35% of the class. The filing breaks ownership into 338,160 common shares and warrants totaling 467,535 (218,000 Series A warrants, 218,000 Series B warrants, and 31,535 Series C warrants) that are exercisable into common stock.
The filer certifies the shares were not acquired to change or influence control. The document lists the issuer's Kuala Lumpur address and the reporter's Malaysian residence, and it attaches warrant forms as exhibits.
Bio Green Med Solution (BGMS) filed a Form 4 reporting insider stock sales by Kua Khai Loon, a Director. On 09/12/2025, the insider sold 22,251 shares of common stock at $6.224 per share, leaving 363,160 shares beneficially owned. On 09/16/2025, the insider sold an additional 25,000 shares at $5.132 per share, with 338,160 shares beneficially owned afterward. Both positions are listed as Direct (D) ownership.
FITTERS Diversified Berhad, a director, reported a sale of $5.293-per-share common stock on 10/08/2025 for 142,000 shares, reducing its stake to 557,158 shares held directly. The Form 4 shows the transaction type as a sale and lists the reporting person’s address in Kuala Lumpur. The form was signed by Datuk Tan Chor How Christopher on 10/10/2025.
Bio Green Med Solution, Inc. reported that its Board of Directors declared a quarterly cash dividend of $0.15 per share on its 6% Convertible Exchangeable Preferred Stock. The dividend will be paid on November 1, 2025 to holders of the Preferred Stock who are on record as of the close of business on October 20, 2025.
Bio Green Med Solution, Inc. has sold certain assets related to Plogosertib, a polo-like kinase 1 inhibitor for advanced cancers and blood cancers, to Tethra Biosciences Inc. for $300,000, with an additional potential milestone payment of $170,000.
The assets include all of the company’s patent rights associated with Plogosertib. The transaction was completed on October 6, 2025 under an Asset Purchase Agreement that includes customary representations, warranties, and covenants between the two Delaware corporations.
Bio Green Med Solution, Inc. reports a board change. On September 19, 2025, independent director Kwang Fock Chong resigned, and the company states his departure was not due to any disagreement over operations, policies, or practices. He will not receive severance or a performance bonus for the partial 2025 year.
Effective September 23, 2025, the Board appointed Soon Ping (“Zara”) Pappas, aged 34, as a new independent director to fill the vacancy. She has more than 10 years of business and medical management experience and will be paid $1,000 per month for board service. The Board now has five directors, three of whom are independent, and has confirmed that key members, including Ms. Pappas, meet Nasdaq and SEC audit committee independence and financial literacy requirements.
Bio Green Med Solution, Inc., formerly Cyclacel Pharmaceuticals, Inc., filed an amended current report to correct a presentation detail only. This Amendment No. 1 to the previously filed report updates the cover page to display the company’s correct new logo that aligns with its updated name and ticker symbol, as previously announced. The company states that no other changes have been made to the original report.
Bio Green Med Solution, Inc. reported that on September 11, 2025 it received a notice from Nasdaq that its 6% Convertible Exchangeable Preferred Stock, trading under the symbol BGMSP, no longer meets Nasdaq Listing Rule 5460(a)(2), which requires a minimum Market Value of Publicly Held Shares of $1 million. Nasdaq determined that this preferred stock had been below that threshold for 30 consecutive business days.
Under Nasdaq Listing Rule 5810(c)(3)(D), the company has 180 calendar days, until March 10, 2026, to regain compliance while the preferred stock continues trading on the Nasdaq Capital Market. The company’s common stock (BGMS) is not affected by this notice. If the preferred stock’s market value meets or exceeds $1 million for at least 10 consecutive business days before March 10, 2026, Nasdaq will confirm a return to compliance; otherwise, Nasdaq staff may move to delist the preferred stock, a decision the company could appeal. The company plans to actively monitor the preferred stock’s market value and consider available options.
FITTERS Diversified Berhad reported beneficial ownership of 699,158 shares of Bio Green Med Solution, Inc. That holding represents 19.99% of the company's common stock and is reported as held with sole voting and sole dispositive power over those shares. The filing states the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The filer is organized in Malaysia and provided Malaysian addresses for both the issuer's principal office and the filer.
FITTERS Diversified Berhad reported initial beneficial ownership of 699,158 shares of Bio Green Med Solution, Inc. (BGMS) common stock on a Form 3 filed after an exchange agreement dated May 6, 2025 that closed on September 12, 2025. The filing lists FITTERS as a director of the issuer and states the shares are held directly. The Form 3 is signed by Datuk Tan Chor How Christopher on September 16, 2025. No derivative securities, option grants, or additional terms are disclosed in the filing.